On 06 November 2018
Suven Life Sciences announced that the grant of 1 product patent from Israel (255994) and 1 product patent from Japan (6397131) corresponding to the New Chemical Entities for treatment of disorders associated with Neurodegenerative diseases are valid through 2036 and 2034 respectively. The granted claims of the patents include the class of selective M1 PAM and 5-HT4 compounds respectively and are being developed as therapeutic agents for neurodegenerative disorders such as treatment of cognitive impairment associated with eurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia etc.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
